Pictet Asset Management Holding SA Takes Position in Upstream Bio, Inc. $UPB

Pictet Asset Management Holding SA bought a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 773,148 shares of the company’s stock, valued at approximately $20,991,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in UPB. AQR Capital Management LLC bought a new stake in Upstream Bio in the first quarter valued at $115,000. Woodline Partners LP raised its holdings in Upstream Bio by 5.8% in the 1st quarter. Woodline Partners LP now owns 557,063 shares of the company’s stock worth $3,409,000 after purchasing an additional 30,552 shares in the last quarter. Creative Planning purchased a new stake in shares of Upstream Bio in the 2nd quarter worth about $154,000. JPMorgan Chase & Co. lifted its position in shares of Upstream Bio by 8.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock worth $181,000 after purchasing an additional 1,275 shares during the period. Finally, Legal & General Group Plc boosted its stake in shares of Upstream Bio by 83.0% during the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after purchasing an additional 1,440 shares in the last quarter.

Wall Street Analysts Forecast Growth

UPB has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. Wall Street Zen lowered Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Evercore cut Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price for the company. in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Upstream Bio currently has an average rating of “Moderate Buy” and an average target price of $39.00.

Upstream Bio Trading Up 2.4%

NASDAQ UPB opened at $9.40 on Friday. Upstream Bio, Inc. has a 12 month low of $7.25 and a 12 month high of $33.68. The stock’s fifty day moving average price is $9.03 and its 200-day moving average price is $20.00. The stock has a market cap of $511.55 million, a P/E ratio of -3.52 and a beta of 1.29.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.06). The firm had revenue of $0.67 million during the quarter, compared to the consensus estimate of $0.52 million. Upstream Bio had a negative return on equity of 36.48% and a negative net margin of 5,026.03%. As a group, analysts forecast that Upstream Bio, Inc. will post -3.02 earnings per share for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.